{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-016281","form_type":"8-K","ticker":"FHTX","cik":"0001822462","company_name":"Foghorn Therapeutics Inc.","filed_at":"2024-04-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.394354+00:00","generated_at":"2026-06-03T22:23:04.314539+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Foghorn appoints Kristian Humer as CFO; notes upcoming pipeline milestones for 2024","bullets":["Kristian Humer appointed CFO effective April 16, replacing interim CFO Stephen DiPalma.","Compensation: $475k base salary, 40% target bonus, $87k signing bonus, 275k-share option award.","Humer brings 14+ years life science financial strategy; previously CFO/CBO at Viridian Therapeutics.","Lead program FHD-286 AML data expected H2 2024; FHD-909 (with Lilly) IND filing on track Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-016281","json":"https://secwatch.observer/filing/0001628280-24-016281.json","markdown":"https://secwatch.observer/filing/0001628280-24-016281.md","text":"https://secwatch.observer/filing/0001628280-24-016281.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822462/000162828024016281/0001628280-24-016281-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822462/000162828024016281/fhtx-20240416.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T22:23:04.314539+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"851ff817a4","claim":"Stephen DiPalma departed as Interim Chief Financial Officer at Foghorn Therapeutics Inc..","evidence_excerpt":"In connection with Mr. Humer’s appointment, Stephen DiPalma, the Company’s Interim Chief Financial Officer, principal financial officer and principal accounting officer, will cease to serve in such roles.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822462/000162828024016281/0001628280-24-016281-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"ceased to serve"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"951836ee12","claim":"Kristian F. Humer was appointed as Chief Financial Officer at Foghorn Therapeutics Inc..","evidence_excerpt":"On April 16, 2024, Foghorn Therapeutics Inc. (the “Company”) announced that Kristian F. Humer had been appointed to serve as the Company’s Chief Financial Officer, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822462/000162828024016281/0001628280-24-016281-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}